Present Title & Affiliation
Chief Medical Officer, Enterome, Paris, France — leading the company’s clinical development and translational oncology programs. Based at Enterome’s headquarters, 94/96 Avenue Ledru-Rollin, 75011 Paris, France.
Scientific Publications
A1. Mellstedt H, Frödin J-E, Biberfeld P, Fagerberg J, Giscombe R, Hernandez A, Masucci G, Li S-L, Steinitz M. Patients treated with a monoclonal antibody (Ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the “internal image of the antigen” (Ab2). Int J Cancer. 1991;48:344–349.
A2. Mellstedt H, Frödin J-E, Ragnhammar P, Masucci G, Ljungberg A, Hjelm A-L, Fagerberg J, Lindemalm C, Österborg A, Wersäll P, Christensson B, Shetye J, Biberfeld P, Makower J, Cedermark B, Erwald R, Nathansson J, Magnusson I, Rieger Å. Therapy of colorectal carcinoma with monoclonal antibodies (MAb 17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol. 1991;30:923–931.
A3. Mellstedt H, Frödin J-E, Masucci G, Ragnhammar P, Fagerberg J, Hjelm A-L, Shetye J, Wersäll P, Österborg A. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol. 1991;18:462–477.
A4. Masucci G, Ragnhammar P, Frödin J-E, Hjelm A-L, Wersäll P, Fagerberg J, Österborg A, Mellstedt H. Chemotherapy and immunotherapy of colorectal cancer. Med Oncol Tumor Pharmacother. 1991;8:207–220.
A5. Mellstedt H, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Masucci G, Ragnhammar P, Wersäll P, Österborg A. Unconjugated monoclonal antibodies (MAb17-1A) alone and in combination with GM-CSF in the treatment of colorectal carcinoma (CRC). In: Klapdor R (ed). Recent Results in Tumor Diagnosis and Therapy. München: W. Zuckschwerdt Verlag; 1992. p. 655–658.
A6. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H. Effect of the monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma—long-lasting complete remissions can be induced. Int J Cancer. 1993;53:751–758.
A7. Fagerberg J, Frödin J-E, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (Ab1). I. May induction of Ab1-reactive T cells and anti-anti-idiotypic antibodies (Ab3) lead to tumor regression after mAb therapy? Cancer Immunol Immunother. 1993;37:264–270.
A8. Rubio C, Munck-Wikland E, Fagerberg J, Strander H, Kuylenstierna R, Kruel C. Further studies on the carcinogen-free interval following exposure in experimental esophageal tumorigenesis. In Vivo. 1993;7:81–84.
A9. Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Immunization effect of monoclonal antibodies against tumor-associated antigens during cancer treatment. Ann N Y Acad Sci. 1993;690:337–339.
A10. Wersäll P, Masucci G, Hjelm A-L, Ragnhammar P, Fagerberg J, Frödin J-E, Merk K, Lindemalm C, Ericson K, Kalin B, Mellstedt H. Low-dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma. Med Oncol Tumor Pharmacother. 1993;10:103–111.
A11. Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (Ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response? Cancer Immunol Immunother. 1994;38:149–159.
A12. Shetye J, Mathiesen T, Fagerberg J, Rubio C. Ear tumours induced by experimental carcinogenesis in rats: excision prevents early death. Int J Colorect Dis. 1994;9:125–127.
A13. Fagerberg J, Stockeld D, Lewensohn R. Combined treatment modalities in esophageal cancer—should chemotherapy be included? Acta Oncol. 1994;33:439–450.
A14. Hjelm A-L, Ragnhammar P, Fagerberg J, Magnusson I, Frödin J-E, Svanström R, Shetye J, Mellstedt H, Wersäll P. Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma: a phase II study. Cancer Biother.1995;10:5–12.
A15. Mellstedt H, Fagerberg J, Frödin J-E, Ragnhammar P, Wersäll P, Österborg A. Targeting with monoclonal antibodies and mechanisms of cell destruction. In: Nilsson O, Mattsson R (eds). Frontiers in Endocrinology: Immunocontraception.Ares-Serono Symposia Publ. 12; 1995. p. 33–42.
A16. Stockeld D, Fagerberg J, Backman L, Lewensohn R, Granström L. Synpunkter på handläggning vid esofaguscancer. Bättre överlevnad av nya metoder? Läkartidningen. 1994;91:2243–2246.
A17. Fagerberg J, Steinitz M, Wigzell H, Askelöf P, Mellstedt H. Human anti-idiotypic antibodies induce humoral and cellular immune responses against colorectal carcinoma-associated antigens. Proc Natl Acad Sci USA. 1995;92:4773–4777.
A18. Ragnhammar P, Frödin J-E, Hjelm A-L, Fagerberg J, Wersäll P, Lindemalm C, Magnusson I, Ewerth S, Thor K, Secher E, Mellstedt H. Different dose regimens of monoclonal antibody (MAb) 17-1A for metastatic colorectal carcinoma therapy. Int J Oncol. 1995;7:1049–1056.
A19. Ragnhammar P, Fagerberg J, Frödin J-E, Wersäll P, Hansson L-O, Mellstedt H. GM-CSF augments induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother.1995;40:367–375.
A20. Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 1995;55:1824–1827.
A21. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm A-L, Mellstedt H, Frödin J-E. Humoral anti-idiotypic and anti-anti-idiotypic immune response in monoclonal antibody 17-1A-treated cancer patients. Cancer Immunol Immunother.1996;42:81–87.
A22. Fagerberg J, Rubio C, Gresser I, Kuylenstierna R, Munck-Wikland E, Strander H. Interferon-α/β can impede development of carcinogen-induced squamous cell tumors in the esophagus of C57Bl mice. Int J Cancer. 1995;62:103–106.
A23. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H. Therapeutic use of unconjugated monoclonal antibody 17-1A with GM-CSF in colorectal carcinoma. Oncology Digest.1995;1:13–14.
A24. Mellstedt H, Fagerberg J, Frödin J-E, Liljefors M, Ragnhammar P. Colorectal carcinoma. In: Marty M (ed). Manual of GM-CSF. Oxford: Blackwell Science; 1996. p. 86–95.
A25. Rubio CA, Sveander M, Munck-Wikland E, Witt H, Fagerberg J. Evaluation of protracted stress in the esophageal mucosa of rats. In Vivo. 1995;9:187–192.
A26. Fagerberg J, Mellstedt H. Anti-idiotypes and cancer. Cancer J. 1995;8:181–184.
A27. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in man. J Pharm Sci. 1996;85:824–827.
A28. Fagerberg J, Ragnhammar P, Mellstedt H. Idiotypic network responses and anti-idiotypes in cancer therapy. In: Shoenfeld Y, Kennedy RC, Ferrone S (eds). Idiotypes in Medicine—Autoimmunity, Infection and Cancer. Elsevier Science BV; 1997. p. 491–498.
A29. Wadhwa M, Bird C, Fagerberg J, Gaines-Das R, Mellstedt H, Ragnhammar P, Thorpe R. Production of neutralizing GM-CSF antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol. 1996;104:351–358.
A30. Fagerberg J. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant in tumor immunotherapy. Med Oncol. 1997;13:155–160.
A31. Wersäll JP, Fagerberg J, Ohlsson L, Rudén U, Boethius J, Mellstedt H. Induction of T- and B-cell responses against the unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient. Int J Cancer. 1998;73:790–794.
A32. Österborg A, Yi Q, Henriksson L, Fagerberg J, et al. Idiotype immunization with GM-CSF in myeloma patients induces CD8 and CD4 MHC-restricted T-cell responses. Blood. 1998;91:2459–2466.
A33. Mellstedt H, Fagerberg J. Cancer vaccines in patients: a new treatment modality? Biotherapy in Cancer. 1997;1:4–10. (Also published in Spanish).
A34. Mellstedt H, Fagerberg J, Österborg A. Vaccination mot cancer snart en behandlingsmöjlighet. Läkartidningen.1998;95:1405–1410.
A35. Österborg A, Fagerberg J, Yi Q, et al. Idiotype-specific auto-T cell immunity and immunotherapy in monoclonal gammopathies. Biomed I. 1998.
A36. Samanci A, Yi Q, Fagerberg J, et al. GM-CSF is essential for strong humoral and cellular responses in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother. 1998;47:131–142.
A37. Fagerberg J, Askelöf P, Wigzell H, Mellstedt H. Induction of CD4⁺ and CD8⁺ Bordetella pertussis toxin S1-specific T cells by synthetic peptides. Cell Immunol. 1999;196:110–121.
A38. Fagerberg J, Gigliotti D, Persson B, et al. Structural and immunologic characterization of human anti-idiotypic antibodies used for immunization of colorectal carcinoma patients. Doctoral thesis, Stockholm University; 1995.
A39. Fagerberg J, Yi Q, Gigliotti D, et al. T-cell epitope mapping of idiotypic monoclonal IgG chains in multiple myeloma. Int J Cancer. 1999;80:671–680.
A40. Stockeld D, Tennvall J, Wagenius G, et al. A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncol. 2001;40:566–573.
A41. Mosolits Sz, Harmenberg U, Rudén U, et al. Autoantibodies against GA733-2 in colorectal carcinoma patients.Cancer Immunol Immunother. 1999;47:315–320.
A42. Mosolits Sz, Steinitz M, Harmenberg U, et al. Immunogenic regions of GA733-2 tumor antigen recognized by autoantibodies in colorectal carcinoma. Cancer Immunol Immunother. 2002;51:209–218.
A43. Hjelm-Skog A-L, Ragnhammar P, Fagerberg J, et al. Clinical effects of monoclonal antibody 17-1A combined with GM-CSF and IL-2 in advanced colorectal carcinoma. Cancer Immunol Immunother. 1999;48:463–470.
A44. Mellstedt H, Fagerberg J, Frödin J-E, et al. Augmentation of immune response with GM-CSF and other hematopoietic growth factors. Curr Opin Hematol. 1999;6:169–175.
A45. Mellstedt H, Fagerberg J, Österborg A. Local low dose soluble GM-CSF significantly augments immune response against tumor antigens in man. Eur J Cancer. 1999;35(Suppl 3):29–32.
A46. Mellstedt H, Fagerberg J, Frödin J-E, et al. Ga733/EpCAM as a target for passive and active immunotherapy in colorectal carcinoma. Ann N Y Acad Sci. 2000;910:254–262.
A47. Stockeld D, Falkmer U, Falkmer S, Backman L, Granström L, Fagerberg J. Response to chemoradiation in esophageal squamous carcinoma: evaluation of prognostic factors. Clin Exp Gastroenterol. 2009;2:41–47.
A48. Lind H, Wagenius G, Stockeld D, Fagerberg J. Gemcitabine treatment in locally advanced or metastatic esophageal carcinoma. Manuscript in preparation.
A49. Stockeld D, Ingelman-Sundberg H, Granström L, Fagerberg J, Backman L. Serial fine-needle cytology in diagnosis of esophageal cancer. Acta Cytol. 2002;46:527–534.
A50. Stockeld D, Fagerberg J, Granström L, Backman L. Percutaneous endoscopic gastrostomy (PEG) for nutrition in esophageal cancer. Eur J Surg. 2001;167:839–844.
A51. Fagerberg J, Shetye J, Mosolits S, et al. Modulation of immune response against anti-idiotypic antibodies by adjuvants in animals expressing the corresponding tumor antigen. Manuscript in preparation.
A52. Frödin J-E, Fagerberg J, Hjelm-Skog A-L, Liljefors M, Ragnhammar P, Mellstedt H. MAb17-1A and cytokines for the treatment of colorectal carcinoma. Hybridoma Hybridomics. 2002;21:99–101.
A53. Hansson L, Rabbani H, Fagerberg J, Österborg A, Mellstedt H. T-cell epitopes within CDR and framework regions of tumor-derived immunoglobulin in multiple myeloma. Blood. 2003;101:4930–4936.
A54. Mosolits S, Campbell F, Litvinov S, Fagerberg J, Crow S, Mellstedt H. Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen-based vaccines. Int J Cancer. 2004;112:669–677.
A55. Ullenhag G, Fagerberg J, Strigard K, Frödin J-E, Mellstedt H. Functional HLA-DR T-cell epitopes of CEA identified in colorectal carcinoma patients immunized with recombinant CEA. Cancer Immunol Immunother. 2004;53:331–337.
A56. Mosolits S, Markovic K, Fagerberg J, Frödin J-E, Rezvany M-R, Kiaii S, Mellstedt H, Jeddi-Tehrani M. T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody. Cancer Immunol Immunother. 2005;54:557-570.
A57. Stockeld D, Fagerberg J, Granström L, Backman L. Esophageal cancer in Stockholm County 1978–1995. Acta Oncol. 2007;46:1075-1084.
A58. Mosolits S, Markovic K, Frödin J-E, Virving L, Magnusson C, Steinitz M, Fagerberg J, Mellstedt H. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased responses against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res. 2004;10:5391-5402.
A59. Twelves C, Wong A, Nowacki M, Abt M, Burris HA III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz J-F, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer (X-ACT Trial). N Engl J Med. 2005;352:2696-2704.
A60. Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frödin J-E. Clinical effects of chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int J Oncol. 2005;26:1581-1589.
A61. Claret L, Girard P, Hoff PM, Van Cutsem E, Blum J, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Model-based prediction of Phase III overall survival in colorectal cancer based on Phase II tumor dynamics. J Clin Oncol.2009;27:4103-4109.
A62. Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle P, Raum T. Side-by-side comparison of five clinically tested anti-EpCAM antibodies reveals distinctive features of Adecatumumab. Cancer Cell Int. 2010;10:44.
A63. Masucci G, Ragnhammar P, Frödin J-E, Hjelm A-L, Wersäll PJ, Fagerberg J, Österborg A, Mellstedt H. Chemotherapy and immunotherapy of colorectal cancer. Med Oncol. 2011;8:207-220.
Abstracts Presented at Scientific Conferences
B1. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Ljungberg A, Masucci G, Österborg A, Mellstedt H. Monoklonala antikroppar (MAb 17-1A) och GM-CSF vid metastaserande colorektal cancer. Abstract presented at the Annual Meeting of the Swedish Medical Society, Stockholm, Sweden; Nov 27–29, 1991.
B2. Mellstedt H, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Masucci G, Ragnhammar P, Wersäll P, Österborg A. Unconjugated monoclonal antibodies (MAb 17-1A) alone and in combination with cytokines in the treatment of colorectal carcinoma (CRC). Abstract presented at the 6th Hamburger Symposium über Tumormarker, Hamburg, Germany; 1991.
B3. Frödin J-E, Fagerberg J, Hjelm A-L, Masucci G, Ragnhammar P, Wersäll P, Mellstedt H. Therapy with the mouse monoclonal antibody (MAb 17-1A) alone or in combination with GM-CSF in metastatic CRC patients. Abstract presented at the 7th Scientific Meeting of the British Oncological Association in Association with the Nordic Cancer Societies, Canterbury, UK; Jul 5–7, 1992.
B4. Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (MAb). Abstract presented at the 3rd International Conference on Idiotypes and Disease, Oslo, Norway; Aug 12–15, 1992.
B5. Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of anti-idiotype (ab2)-reactive T cells in cancer patients treated with monoclonal antibodies (ab1). Abstract presented at the 45th Annual Symposium on Fundamental Cancer Research, Houston, USA; Oct 20–23, 1992.
B6. Mellstedt H, Ragnhammar P, Frödin J-E, Fagerberg J, Merk K, Hjelm A-L, Ekman E, Lindemalm C. MAb17-1A and GM-CSF for the treatment of metastatic colorectal carcinoma. Abstract presented at the 2nd International Congress on Biological Response Modifiers, San Diego, USA; Jan 29–31, 1993.
B7. Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Immunization effect of monoclonal antibodies against tumor-associated antigens during treatment of cancer patients. Abstract presented at the 175th Anniversary Conference of The New York Academy of Sciences: Specific Immunotherapy of Cancer with Vaccines, Washington, USA; Jan 21–24, 1993.
B8. Frödin J-E, Fagerberg J, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Clinical relevance of an idiotypic cellular response in CRC patients treated with MAb 17-1A. Abstract presented at the 10th International Hammersmith Conference on Monoclonal Antibodies in Clinical Oncology, Paphos, Cyprus; May 3–5, 1993.
B9. Ragnhammar P, Hjelm A-L, Frödin J-E, Fagerberg J, Wersäll P, Mellstedt H. Monoclonal antibodies combined with cytokines in advanced colorectal carcinoma. Abstract presented at ECCO 7, Jerusalem, Israel; Nov 14–18, 1993.
B10. Steinitz M, Fagerberg J, Frödin J-E, Ragnhammar P, Wigzell H, Mellstedt H. Induction of anti-idiotypic reactive T cells in cancer patients treated with monoclonal antibodies. Abstract presented at the Annual Meeting of the Israeli Immunology Society, Israel; 1993.
B11. Hjelm A-L, Ragnhammar P, Fagerberg J, Frödin J-E, Mellstedt H, Wersäll P. Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma (a phase II clinical study). Abstract presented at the Annual Meeting of the International Society for Interferon Research (ISIR), Tokyo, Japan; Oct 24–28, 1993.
B12. Fagerberg J, Frödin J-E, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Idiotypic immune responses in cancer patients treated with monoclonal antibodies. Abstract presented at the ENII Conference: Integrated Function of Molecules of the Immune System, Île des Embiez, France; May 12–16, 1993.
B13. Rudén U, Fagerberg J, Harmenberg U, Mellstedt H, Wahren B. Epitopes of a carcinoma-associated antigen.Abstract presented at the 13th American Peptide Symposium, Edmonton, Canada; Jun 20–25, 1993.
B14. Fagerberg J, Askelöf P, Wigzell H, Steinitz M, Mellstedt H. Immunization with human anti-idiotypic antibodies in patients operated for colorectal cancer. Abstract presented at the 1st International Conference on Engineered Vaccines for Cancer and AIDS, San Francisco, USA; Sep 3–Oct 2, 1993.
B15. Stockeld D, Tisell Å, Lewensohn R, Fagerberg J, Granström L, Backman L. Evaluation of oncologic treatment of esophageal cancer with endoscopic ultrasound and CT. Abstract presented at the Annual Meeting of the Swedish Surgical Society, Stockholm, Sweden; Mar 25–26, 1993.
B16. Fagerberg J, Tenvall J, Stockeld D, Lewensohn R, Strander H, Hambraeus G, Backman L, Granström L, Åberg B. Neoadjuvant treatment of esophageal cancer with chemoradiotherapy and surgery. Abstract presented at the Annual Meeting of the Swedish Medical Society, Stockholm, Sweden; Dec 1–3, 1993.
B17. Hjelm A-L, Ragnhammar P, Fagerberg J, Frödin J-E, Mellstedt H, Wersäll P. Subcutaneous administration of interleukin-2 and alpha-interferon in advanced colorectal cancer: a Phase II study. Abstract presented at the Annual Meeting of the Swedish Medical Society, Stockholm, Sweden; Dec 1–3, 1993.
B18. Fagerberg J, Askelöf P, Wigzell H, Steinitz M, Mellstedt H. Immunization of post-surgical colorectal cancer patients with human anti-idiotypic antibodies. Abstract presented at the Annual Meeting of the Swedish Medical Society, Stockholm, Sweden; Dec 1–3, 1993.
B19. Fagerberg J, Steinitz M, Wigzell H, Persson M, Gigliotti D, Askelöf P, Rudén U, Wahren B, Mellstedt H. Anti-idiotypic antibodies for immunization against tumor-associated antigens in humans. Abstract presented at the 85th Annual Meeting of the American Association for Cancer Research (AACR), San Francisco, USA; Apr 10–13, 1994.
B20. Fagerberg J, Steinitz M, Wigzell H, Persson M, Gigliotti D, Askelöf P, Rudén U, Wahren B, Mellstedt H. Anti-idiotypic antibodies for immunization against tumor-associated antigens in humans. Abstract presented at the 1st Educational Convention of the European School of Oncology, Paris, France; Jun 16–18, 1994. Eur J Cancer.1994;30A(Suppl 1):S11.
B21. Ragnhammar P, Fagerberg J, Frödin J-E, Mellstedt H. Induction of anti-idiotypic antibodies in patients treated with monoclonal antibodies is enhanced by GM-CSF. Abstract presented at the XVI International Cancer Congress, New Delhi, India; Oct 30–Nov 5, 1994.
B22. Shetye J, Ragnhammar P, Frödin J-E, Fagerberg J, Biberfeld P, Christensson B, Mellstedt H. Immune reactions in tumor lesions of CRC patients treated with MAb 17-1A alone or combined with GM-CSF. Abstract presented at the XVI International Cancer Congress, New Delhi, India; Oct 30–Nov 5, 1994.
B23. Fagerberg J, Steinitz M, Wigzell H, Persson M, Gigliotti D, Askelöf P, Rudén U, Wahren B, Mellstedt H. Anti-idiotypic antibodies for immunization against tumor-associated antigens in humans. Abstract presented at the XVI International Cancer Congress, New Delhi, India; Oct 30–Nov 5, 1994.
B24. Fagerberg J, Mellstedt H. Idiotypes and anti-idiotypes in cancer treatment: utilization of humoral and cellular idiotypic network responses for antitumor effects. Abstract presented at the XVI International Cancer Congress, New Delhi, India; Oct 30–Nov 5, 1994.
B25. Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Mellstedt H. Idiotypic network responses and clinical correlation in cancer patients treated with monoclonal antibodies. Abstract presented at the 2nd International Symposium on Biomedical Diagnostic & Prognostic Indicators, Boston, USA; Dec 11–13, 1994. Cancer Detect Prev.1995;19:121-122.
B26. Mellstedt H, Fagerberg J, Frödin J-E, Hjelm A-L, Ragnhammar P. Monoclonal antibodies and cytokines for metastatic CRC: is the idiotypic network response an important effector function? Abstract presented at the 3rd International Congress on Biological Response Modifiers, Cancún, Mexico; Jan 26–29, 1995.
B27. Fagerberg J, Shetye J, Rubio C, Herlyn D, Wigzell H, Mellstedt H. Influence of adjuvants on induction of immune responses at immunization with syngeneic anti-idiotypic antibodies. Abstract presented at the 2nd International Conference on Engineered Vaccines for Cancer and AIDS, San Francisco, USA; Mar 3–5, 1995. Cancer Biother.1995;10:86.
B28. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Mellstedt H. Monoclonal antibodies and cytokines for metastatic CRC: idiotypic network response as effector mechanism? Abstract presented at the Jakarta International Cancer Conference, Jakarta, Indonesia; May 28–Jun 2, 1995.
B29. Bird C, Wadhwa M, Thorpe R, Ragnhammar P, Frödin J-E, Mellstedt H, Fagerberg J. Production of GM-CSF antibodies in carcinoma patients following GM-CSF therapy. Abstract presented at the International Cytokine Society Meeting, UK; 1995.
B30. Ragnhammar P, Fagerberg J, Liljefors M, Hjelm A-L, Mellstedt H, Frödin J-E. Humoral anti-idiotypic and anti-anti-idiotypic immune responses in MAb 17-1A-treated patients. Abstract presented at the 5th International Conference of Anticancer Research, Corfu, Greece; Oct 17–22, 1995.
B31. Mellstedt H, Bergenbrant S, Fagerberg J, Gigliotti D, Grunewald J, Halapi E, Holm G, Lefvert A-K, Wahlström J, Werner Å, Wigzell H, Yi Q, Österborg A. Auto T-cell immunity in monoclonal gammopathies. Abstract presented at the 5th International Workshop on Multiple Myeloma, La Baule, France; Sep 10–13, 1995.
B32. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex.Abstract presented at the 7th International Symposium on Platinum and Other Coordination Compounds in Cancer Chemotherapy, Amsterdam, Netherlands; Mar 1–4, 1995.
B33. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex.Abstract presented at the 55th World Congress of Pharmacy and Pharmaceutical Sciences, Stockholm, Sweden; Aug 27–Sep 1, 1995.
B34. Fagerberg J, Samanci A, Yi Q, Strigård K, Frödin J-E, Wahren B, Rudén U, Mellstedt H. Recombinant carcinoembryonic antigen and GM-CSF for active immunization of colorectal carcinoma patients. Abstract presented at the 10th Annual Scientific Meeting of the Society for Biological Therapy, Williamsburg, USA; Nov 1–4, 1995. J Immunother. 1995;18:132.
B35. Fagerberg J, Tennvall J, Stockeld D, Lewensohn R. Phase II study on chemoradiation and surgery for squamous cell carcinoma of the esophagus. Abstract presented at the 6th International Congress on Anti-Cancer Treatment, Paris, France; Feb 6–9, 1996.
B36. Strigård K, Fagerberg J, Yi Q, Frödin J-E, Mellstedt H, Rudén U, Wahren B. Active immunization with recombinant CEA and GM-CSF in colorectal cancer. Abstract presented at the Annual Meeting of the Swedish Medical Society, Stockholm, Sweden; Nov 29–Dec 1, 1995.
B37. Fagerberg J, Mellstedt H. Anti-idiotypes in colorectal cancer patients. Abstract presented at the 3rd International Meeting on Idiotypic Network and Tumor Therapy, Bonn, Germany; Feb 29–Mar 2, 1996.
B38. Jeddi-Tehrani M, Gigliotti D, Österborg A, Fagerberg J, Mellstedt H. A sensitive technique for detection of minimal residual disease in myeloma patients. Abstract presented at the 2nd Meeting of the European Haematology Association, Paris, France; May 29–Jun 1, 1996.
B39. Fagerberg J, Mellstedt H. Effector functions of unconjugated mAbs in vivo and clinical results in cancer patients.Abstract presented at the XXIV Convegno Nazionale – IFIS-SSI Joint Meeting on Tumor Immunology, L’Aquila, Italy; Jun 13–15, 1996.
B40. Mellstedt H, Fagerberg J, Rudén U, Samanci A, Strigård K, Wahren B, Yi Q, Österborg A. Monitoring immune response to tumor antigens and development of cancer vaccines. Abstract presented at Cancer Vaccines, New York, USA; Oct 7–9, 1996.
B41. Österborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Lefvert A-K, Holm G, Mellstedt H. Idiotype immunization with GM-CSF in myeloma patients induces CD8⁺ T-cell response and tumor regression. Abstract presented at the 38th Annual Meeting of the American Society of Hematology (ASH), Orlando, FL, USA; Dec 6–10, 1996.
B42. Fagerberg J, Samanci A, Yi Q, Strigård K, Rudén U, Wahren B, Mellstedt H. Recombinant carcinoembryonic antigen and GM-CSF for active immunization of colorectal carcinoma patients. Abstract presented at the 11th Annual Scientific Meeting of the Society for Biological Therapy, Washington, DC, USA; Oct 23–27, 1996. J Immunother.1996;19:461.
B43. Fagerberg J, Samanci A, Yi Q, Strigård K, Rudén U, Wahren B, Mellstedt H. Recombinant carcinoembryonic antigen and GM-CSF for active immunization of colorectal carcinoma patients. Abstract presented at the 7th International Congress on Anti-Cancer Treatment, Paris, France; Feb 3–6, 1997.
B44. Fagerberg J. Different types of tumor vaccine strategies and an overview of clinical trials. Abstract presented at Oncology Year 2010 – A Conjecture of Therapeutic Strategies, Stockholm, Sweden; Nov 26, 1996.
B45. Österborg A, Fagerberg J, Yi Q, Bergenbrant S, Jeddi-Tehrani M, Henriksson L, Lefvert A-K, Holm G, Mellstedt H. Idiotype-specific auto-T cell immunity and immunotherapy in monoclonal gammopathies. In: Proceedings of the Workshop on Idiotypic Vaccination, Turin, Italy; Nov 14–15, 1996.
B46. Fagerberg J, Samanci A, Strigård K, Rudén U, Mellstedt H. Induction of specific T cells after immunization with baculovirus-produced recombinant tumor-associated antigens: mapping of T-cell epitopes. Abstract presented at the 12th Annual Scientific Meeting of the Society for Biological Therapy, Pasadena, CA, USA; Oct 22–25, 1997.
B47. Stockeld D, Tennvall J, Wagenius G, Lewensohn R, Backman L, Granström L, Gustafsson G, Gustavsson S, Hambraeus G, Sjöstedt S, Åberg B, Fagerberg J. Preoperative full-dose radiochemotherapy with cisplatin and 5-fluorouracil in esophageal squamous carcinoma: a Phase II study. Abstract presented at the Annual Meeting of the Swedish Medical Society, Stockholm, Sweden; Nov 26–28, 1997.
B48. Fagerberg J, Stockeld D, Tennvall J, Wagenius G. Phase II study on chemoradiation and surgery for squamous-cell carcinoma of the esophagus. Abstract presented at the 8th International Congress on Anti-Cancer Treatment, Paris, France; Feb 3–6, 1998.
B49. Mosolits S, Fagerberg J, Rudén U, Harmenberg U, Mellstedt H. Autoantibodies against peptide epitopes of the GA733-2 tumor-associated antigen in colorectal cancer patients. Abstract presented at the 3rd Educational Convention of the European School of Oncology, Turin, Italy; May 28–30, 1998. Eur J Cancer. 1998;34(Suppl 2).
B50. Mosolits S, Fagerberg J, Rudén U, Harmenberg U, Mellstedt H. Autoantibodies against peptide epitopes of the GA733-2 tumor-associated antigen in colorectal cancer patients. Abstract presented at the European Association for Cancer Research Annual Meeting, Stockholm, Sweden; Aug 15–19, 1998.
B51. Fagerberg J, Samanci A, Strigård K, Rudén U, Mellstedt H. Immunization of colorectal carcinoma patients with recombinant tumor-associated antigens—mapping of T-cell epitopes. Abstract presented at the 3rd International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Cologne, Germany; Sep 23–26, 1998.
B52. Lind H, Stockeld D, Sjöstedt S, Ramel S, Granström L, Backman L, Fagerberg J. Phase II study on chemoradiation and surgery for adenocarcinoma of the esophagus and cardia. Abstract presented at the 3rd International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Cologne, Germany; Sep 23–26, 1998.
B53. Fagerberg J, Mosolits S, Frödin J-E, Rudén U, Mellstedt H. Anti-tumor antigen immune responses after immunization with human anti-idiotypes (Ab2) and/or recombinant antigen + GM-CSF. Abstract presented at the 13th Annual Meeting of the Society for Biological Therapy, Pittsburgh, PA, USA; Oct 21–24, 1998.
B54. Mellstedt H, Fagerberg J, Henriksson L, Samanci A, Österborg A. Local low-dose soluble GM-CSF significantly augments immune responses against tumor antigens in humans. Abstract presented at Cancer Vaccine Week, New York, USA; Oct 5–9, 1998.
B55. Fagerberg J, Frödin J-E, Hjelm-Skog A-L, Liljefors M, Mellstedt H. Effector functions of unconjugated monoclonal antibodies in vivo and clinical results in cancer patients. Abstract presented at the 9th International Congress on Anti-Cancer Treatment, Paris, France; Feb 2–5, 1999.
B56. Lind H, Wagenius G, Stockeld D, Fagerberg J. Pilot study on gemcitabine treatment in advanced esophageal carcinoma. Abstract presented at the 9th International Congress on Anti-Cancer Treatment, Paris, France; Feb 2–5, 1999.
B57. Mosolits S, Fagerberg J, Rudén U, Harmenberg U, Mellstedt H. Natural autoantibodies against peptide epitopes of GA733-2 tumor-associated antigen. Abstract presented at the 2nd International Congress on Autoimmunity, Tel Aviv, Israel; Mar 7–12, 1999.
B58. Fagerberg J, Mosolits S, Markovic K, Rudén U, Frödin J-E, Mellstedt H. Immunization of colorectal carcinoma patients using human anti-idiotypes (Ab2) and/or recombinant antigen: mapping of T-cell epitopes. Abstract presented at the Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, USA; Apr 10–14, 1999.
B59. Mellstedt H, Österborg A, Fagerberg J, Henriksson L, Jeddi-Tehrani M, Rezvany MR. Natural and induced idiotype immunity—IgHV-CDR regions as potential vaccine targets. Abstract presented at the Experts’ Round Table on Immune Therapy, Stockholm, Sweden; Aug 31–Sep 1, 1999.
B60. Mellstedt H, Österborg A, Fagerberg J, Henriksson L. Natural idiotype immunity in multiple myeloma. Abstract presented at the 7th International Multiple Myeloma Workshop, Stockholm, Sweden; Sep 1–5, 1999.
B61. Hjelm-Skog A-L, Ragnhammar P, Fagerberg J, Frödin J-E, Liljefors M, Shetye J, Wersäll P, Mellstedt H. Combining MAb 17-1A with GM-CSF and IL-2 in advanced colorectal carcinoma. Abstract presented at the 14th Annual Meeting of the Society for Biological Therapy, Boston, USA; Oct 1999. J Immunother. 1999;22(5).
B62. Albertsson M, Fagerberg J, Jacobsen A-B, Jasinski M, Lewin F, Johansson B, Kadar L, Loden B, Modig G, Wagenius G. Phase II study of docetaxel (Taxotere) in patients with primary untreated or recurrent esophageal cancer.Abstract presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), New Orleans, LA, USA; May 20–23, 2000.
B63. Markovic K, Mosolits S, Fagerberg J, Frödin J-E, Mellstedt H. Active immunization of colorectal carcinoma patients with recombinant GA733-2 antigen and/or human anti-idiotypic antibodies (h-Ab2). Abstract presented at the 25th European Society for Medical Oncology (ESMO) Congress, Hamburg, Germany; Oct 13–17, 2000. Ann Oncol.2000;11:42–43.
B64. Mosolits S, Campbell F, Litvinov SV, Fagerberg J, Crowe JS, Mellstedt H, Ellis JH. Gene gun-mediated DNA vaccination with idiotype/GM-CSF fusion gene induces anti-EpCAM responses in transgenic mice. Abstract presented at the 8th International Conference on Human Antibodies and Hybridomas, Prague, Czech Republic; Apr 23–25, 2001.
B65. Frödin J-E, Fagerberg J, Markovic K, Mosolits S, Mellstedt H. Immunization with a human anti-idiotypic antibody and/or the nominal antigen in colorectal carcinoma patients. Abstract presented at Advances in the Application of Monoclonal Antibodies in Clinical Oncology, Vouliagmeni, Greece; Jun 13–15, 2001.
B66. Ahlgren J, Lidbrink E, Lind B, Malmberg L, Söderberg M, Carlsson L, Fornander T, Svensson J-H, Villman K, Fagerberg J. Phase II study of epirubicin, cisplatin, and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Abstract presented at ASCO Annual Meeting, Chicago, IL, USA; May 31–Jun 3, 2003.
B67. Liljefors M, Fagerberg J, Nilsson B, Ragnhammar P, Mellstedt H, Frödin J-E. Clinical effects of chimeric anti-EpCAM monoclonal antibody and GM-CSF in metastatic colorectal carcinoma. Abstract (314P) presented at the ESMO Congress, Vienna, Austria; Oct 29–Nov 2, 2004. Ann Oncol. 2004;15(Suppl 3):84.
B68. Fagerberg J. Oncology pipeline – Roche development. Abstract presented at the ESO Spring Masterclass in Clinical Oncology, Cyprus; Mar 6–11, 2004.
B69. Fagerberg J. Biomarkers in oncology drug development: hope and reality. Abstract presented at the ESO 5th Masterclass in Clinical Oncology, St. Julians, Malta; Feb 11–17, 2006.
B70. Claret L, Blum J, O’Shaughnessy J, Hoff P, Van Cutsem E, Girard P, Zuideveld KP, Jorga K, Fagerberg J, Reigner B. Model-based predictions of anti-tumor response and survival in Phase III studies based on Phase II data of an investigational agent. Abstract presented at the ASCO Annual Meeting, Atlanta, USA; Jun 2006.
B71. Cassidy J, Clarke S, Cunningham D, Van Cutsem E, Hoff P, Rothenberg M, Saltz L, Schmoll H-J, Allegra C, Bertino J, Douillard J-Y, Gustavsson B, Milano G, O’Connell M, Rustum Y, Tabernero J, Fagerberg J, Gilberg F, Sirzen F, Twelves C. Regional differences in tolerability of fluoropyrimidines. Abstract #3514 presented at the ASCO Annual Meeting, Atlanta, USA; Jun 2006.
B72. Northfelt DW, Bonnem E, Fagerberg J, Von Hoff D, Grem J. Belinostat downregulates thymidylate synthase in tumor tissue: a dose-escalation study of belinostat alone and with 5-FU. Abstract presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA; Jan 2009.
B73. Kelly WK, de Bono J, Blumenschein G, Lassen U, Zain J, O’Connor O, Foss F, Tjornelund J, Fagerberg J, Petrylak D. Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. Abstract presented at the ASCO Annual Meeting, Orlando, FL, USA; May–Jun 2009.
B74. Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T. Inhibition of breast cancer cell proliferation and unique epitope recognition by EpCAM-specific human monoclonal antibody Adecatumumab. Abstract #5339 presented at the AACR Annual Meeting, Washington, DC, USA; Apr 2010. Cancer Res. 2010;70(Suppl 8):5339.
B75. Havel L, Kolek V, Pesel M, Zemanova M, Bartunokova J, Fagerberg J, Spisek R, Krasnopolskaya I. Phase I/II study evaluating safety and efficacy of DCVAC/LuCa with first-line chemotherapy ± immune enhancers vs chemotherapy in stage IV NSCLC. Abstract P3.06-001 presented at the 17th World Conference on Lung Cancer (IASLC), Vienna, Austria; Dec 2016. J Thorac Oncol. 2017;12(Suppl):S1424.